Juno Therapeutics, Inc. (NASDAQ:JUNO) was downgraded by investment analysts at Vetr from a “hold” rating to a “sell” rating in a note issued to investors on Monday. They presently have a $28.47 price objective on the biopharmaceutical company’s stock. Vetr‘s price objective indicates a potential downside of 1.49% from the company’s current price.

JUNO has been the topic of a number of other reports. Leerink Swann restated an “outperform” rating on shares of Juno Therapeutics in a report on Monday, June 12th. Zacks Investment Research upgraded Juno Therapeutics from a “hold” rating to a “buy” rating and set a $32.00 price target on the stock in a report on Tuesday, July 11th. BidaskClub lowered Juno Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, June 10th. BTIG Research lowered Juno Therapeutics from a “neutral” rating to a “sell” rating and boosted their price target for the company from $22.60 to $23.73 in a report on Thursday, June 8th. Finally, Wedbush restated a “neutral” rating and issued a $24.00 price target on shares of Juno Therapeutics in a report on Friday, May 5th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and seven have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $30.86.

Juno Therapeutics (NASDAQ JUNO) opened at 28.90 on Monday. Juno Therapeutics has a 12 month low of $17.52 and a 12 month high of $35.04. The firm has a 50-day moving average price of $28.51 and a 200 day moving average price of $24.26. The firm’s market capitalization is $3.01 billion.

Juno Therapeutics (NASDAQ:JUNO) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by $0.24. The firm had revenue of $21.30 million during the quarter, compared to the consensus estimate of $15.59 million. Juno Therapeutics had a negative net margin of 354.36% and a negative return on equity of 27.10%. The business’s revenue for the quarter was down 22.8% on a year-over-year basis. During the same quarter last year, the firm earned ($0.64) earnings per share. On average, equities analysts forecast that Juno Therapeutics will post ($3.05) EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Vetr Inc. Lowers Juno Therapeutics, Inc. (NASDAQ:JUNO) to Sell” was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US & international copyright legislation. The legal version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/09/vetr-inc-lowers-juno-therapeutics-inc-nasdaqjuno-to-sell.html.

In related news, major shareholder Douglas K. Bratton sold 8,000,000 shares of Juno Therapeutics stock in a transaction dated Thursday, July 13th. The stock was sold at an average price of $27.00, for a total value of $216,000,000.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Steve Harr sold 8,750 shares of Juno Therapeutics stock in a transaction dated Tuesday, June 27th. The shares were sold at an average price of $30.00, for a total value of $262,500.00. Following the completion of the sale, the chief financial officer now directly owns 736,189 shares in the company, valued at approximately $22,085,670. The disclosure for this sale can be found here. In the last ninety days, insiders sold 8,041,500 shares of company stock worth $217,230,360. 15.26% of the stock is owned by company insiders.

Hedge funds have recently added to or reduced their stakes in the stock. M&T Bank Corp bought a new stake in Juno Therapeutics during the first quarter worth about $381,000. Norges Bank bought a new stake in Juno Therapeutics during the fourth quarter worth about $13,993,000. Nisa Investment Advisors LLC bought a new stake in Juno Therapeutics during the first quarter worth about $200,000. Laurion Capital Management LP bought a new stake in Juno Therapeutics during the first quarter worth about $390,000. Finally, BB Biotech AG increased its stake in Juno Therapeutics by 16.8% in the first quarter. BB Biotech AG now owns 2,185,000 shares of the biopharmaceutical company’s stock worth $48,485,000 after buying an additional 315,000 shares in the last quarter. 64.60% of the stock is currently owned by institutional investors and hedge funds.

About Juno Therapeutics

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

To view Vetr’s full report, visit Vetr’s official website.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.